[DOI] [PubMed] [Google Scholar] 9.Brmme H., Mrke W., Peschke E., Ebelt H., Peschke D
Currently, there is an ongoing randomised double-masked placebo-controlled trial, the SUMMIT trial, studying the efficacy and safety of tirzepatide, a dual agonist of glucose-dependent insulinotropic polypeptide and GLP-1 receptors, versus placebo in HFpEF patients with obesity (NCT04847557)
If you have been wondering whether insurance covers tirzepatide or whether Anthem covers GLP-1 medications , compounded versions typically are not covered
Researchers have noted that the two peptides appear to work through distinct but synergistic pathways
Its testing detected significant levels of a reaction-related impurity in all 10 samples Lilly obtained from compounding pharmacies, telehealth companies, and med spas
Yes, based on current research models